Rossmax International (4121) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 優盛

Rossmax International (4121) reported revenue of NT$342.3 million for Oct 2026, +10.2% year on year and +4.2% from the previous month. Revenue for Jan–Oct 2026 was NT$3.21 billion (+1.7% year on year).

Year-on-year revenue growth: 5 months in a row. →

In Oct 2026, it ranked No. 28 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$297.8 million24/10Nov 2024 NT$327.9 millionDec 2024 NT$344 millionJan 2025 NT$331 millionFeb 2025 NT$285.1 million25/02Mar 2025 NT$309.7 millionApr 2025 NT$331.3 millionMay 2025 NT$329.4 millionJun 2025 NT$321.1 million25/06Jul 2025 NT$320.8 millionAug 2025 NT$319.4 millionSep 2025 NT$300.9 millionOct 2025 NT$310.7 million25/10Nov 2025 NT$333.2 millionDec 2025 NT$307.1 millionJan 2026 NT$323.8 millionFeb 2026 NT$298.1 million26/02Mar 2026 NT$316.4 millionApr 2026 NT$300.9 millionMay 2026 NT$317.9 millionJun 2026 NT$327.9 million26/06Jul 2026 NT$324.5 millionAug 2026 NT$332.2 millionSep 2026 NT$328.6 millionOct 2026 NT$342.3 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$342.3 million+10.2%+4.2%
Sep 2026NT$328.6 million+9.2%-1.1%
Aug 2026NT$332.2 million+4.0%+2.4%
Jul 2026NT$324.5 million+1.2%-1.0%
Jun 2026NT$327.9 million+2.1%+3.2%
May 2026NT$317.9 million-3.5%+5.6%
Apr 2026NT$300.9 million-9.2%-4.9%
Mar 2026NT$316.4 million+2.2%+6.1%
Feb 2026NT$298.1 million+4.6%-7.9%
Jan 2026NT$323.8 million-2.2%+5.4%
Dec 2025NT$307.1 million-10.7%-7.8%
Nov 2025NT$333.2 million+1.6%+7.2%
Oct 2025NT$310.7 million+4.3%+3.2%
Sep 2025NT$300.9 million-4.7%-5.8%
Aug 2025NT$319.4 million-2.4%-0.4%
Jul 2025NT$320.8 million-3.1%-0.1%
Jun 2025NT$321.1 million+2.2%-2.5%
May 2025NT$329.4 million+5.6%-0.6%
Apr 2025NT$331.3 million-0.5%+7.0%
Mar 2025NT$309.7 million+1.5%+8.6%
Feb 2025NT$285.1 million-8.5%-13.8%
Jan 2025NT$331 million-0.3%-3.8%
Dec 2024NT$344 million+0.6%+4.9%
Nov 2024NT$327.9 million+5.5%+10.1%
Oct 2024NT$297.8 million-4.2%-5.7%

Jan–Oct 2026 cumulative: NT$3.21 billion (+1.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Rossmax International vs PEC / Rossmax International vs Lotus Pharm / Rossmax International vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16